azacitidine has been researched along with eicosapentaenoic acid in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Billi, M; Binaglia, L; Ceccarelli, V; Grignani, F; Nocentini, G; Racanicchi, S; Riccardi, C; Roberti, R; Vecchini, A | 1 |
2 other study(ies) available for azacitidine and eicosapentaenoic acid
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Eicosapentaenoic acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells.
Topics: Azacitidine; Base Sequence; CCAAT-Enhancer-Binding Protein-delta; CpG Islands; DNA Methylation; Eicosapentaenoic Acid; Exons; Humans; Introns; Leukemia; MAP Kinase Signaling System; Membrane Microdomains; Molecular Sequence Data; Phosphorylation; Protein Binding; Protein Isoforms; Proto-Oncogene Proteins p21(ras); RNA Polymerase II; Transcription, Genetic; Tumor Suppressor Protein p53; U937 Cells | 2014 |